Month: October 2026

Efficient Cell Line Development as Biotech Capital Concentrates

Efficient Cell Line Development as Biotech Capital Concentrates Efficient cell line development is now a budgeting question as much as a scientific one. J.P. Morgan’s Q3 2026 biopharma and medtech deal report, published October 20, puts biopharma venture funding at $23.9 billion across 385 rounds year to date. Funding moderated in the third quarter, and … Continue reading Efficient Cell Line Development as Biotech Capital Concentrates

CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development

CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development CHO cell glycosylation shapes how a therapeutic protein behaves in the body. Glycan structures influence half-life, effector function, and immunogenicity. Therefore small shifts in a culture can move a product’s quality profile. A review in Frontiers in Bioengineering and Biotechnology, published in August … Continue reading CHO Cell Glycosylation: What New Engineering Data Means for Cell Line Development

ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate

ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate Antibody-drug conjugates remain one of the hottest areas in oncology. As of June 30, 2026, 23 ADCs had regulatory approval worldwide. In addition, China approved izalontamab brengitecan on June 22, 2026, reported as the first approved bispecific ADC. Payloads and linkers get most of … Continue reading ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate

Bispecific Antibody Production: Cell Line Strategies for Getting the Pairing Right

Bispecific Antibody Production: Cell Line Strategies for Getting the Pairing Right Bispecific antibodies have become one of the busiest areas in biologics. At least 15 now have FDA approval, including emicizumab, teclistamab, and faricimab. Bispecifics also featured in some of the highest-value antibody partnerships of early 2026. Yet bispecific antibody production remains harder than standard … Continue reading Bispecific Antibody Production: Cell Line Strategies for Getting the Pairing Right

AI in Cell Line Development: What Machine Learning Can and Cannot Do Yet

AI in Cell Line Development: What Machine Learning Can and Cannot Do Yet AI is dominating biotech headlines, and regulators are paying attention. In January 2025, FDA released its first draft guidance on AI for drug and biologic regulatory decisions. Meanwhile, researchers are testing AI in cell line development to identify strong clones sooner. The … Continue reading AI in Cell Line Development: What Machine Learning Can and Cannot Do Yet